Tax season.
This single-arm phase 2 trial achieved freedom from progression at 12 weeks for over half of patients receiving cabazitaxel for metastatic or refractory dedifferentiated liposarcoma. | Sanfilippo, JAMA Oncol 2022
Search This Blog
With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
- Get link
- Other Apps
Comments
Post a Comment